Across TCGA pan-cancer cohorts, COX16 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated COX16 data layer compared with 25 for mass-spec protein and 2 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher COX16 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated COX16 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.
HNSC and CCRCC are the cancer types where COX16 mass-spec protein most reproducibly stratifies survival.